| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | TV-45070 | Postherpetic neuralgia | Phase 2b | Trial Discontinued | Topical | Neurology |
| Xenon Pharmaceuticals Inc. | Azetukalner - (IIT) | Major depressive disorder (MDD) | Phase 2 | Data Released | Intrathecal | Psychiatric |
| Xenon Pharmaceuticals Inc. | NBI-921352 | SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) | Phase 2 | Trial Discontinued | Oral | Neurology |
| Xenon Pharmaceuticals Inc. | XEN007 | Childhood absence epilepsy | Phase 2 | Trial Discontinued | Oral | Neurology |
| Xenon Pharmaceuticals Inc. | XEN801 | Acne | Phase 2 | Trial Discontinued | Topical | N/A |
| Xenon Pharmaceuticals Inc. | TV-45070 | Osteoarthritis | Phase 2a | Trial Discontinued | Topical | Orthopedic |
| Xeris Biopharma Holdings Inc. | COR-003 (levoketoconazole) - (LOGICS) | Endogenous Cushing’s syndrome | Phase 3 | Data Released | oral | Endocrinology |
| Xeris Biopharma Holdings Inc. | Self administered glucagon | Post-Bariatric Hypoglycemia | Phase 2b | Trial Completed | Intranasal or subcutaneous | Endocrinology |